Impact of PEG Bowel Preparation on Gut Microbiome Composition Recovery
Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Feb 13, 2025
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special bowel preparation called PEG (polyethylene glycol) affects the gut microbiome, which is the community of bacteria and other microorganisms living in our intestines. The goal is to see how this preparation changes the types and numbers of these microbes after it’s used, which is important for understanding gut health, especially for people with cancer. The trial is currently recruiting participants, and anyone aged 18 or older who is healthy and willing to follow the study guidelines can potentially join.
To participate, individuals must not have certain health issues, such as severe bowel blockages or recent antibiotic use, and they need to be able to safely swallow the preparation. Participants will need to take the PEG bowel preparation and provide stool samples for analysis. This is a chance to contribute to research that could help improve gut health in cancer patients and others. If you’re considering joining, it’s important to discuss any health concerns with your doctor to ensure you meet the eligibility requirements.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Healthy volunteer participant cohort:
- • 1. \> 18 years of age
- • 2. The participant has provided documented informed consent for the participation and to complete PEG bowel preparation and return collected stool samples.
- Exclusion Criteria:
- • An ileus
- • Significant gastric retention
- • Suspected or established mechanical bowel obstruction
- • Inflammatory or infectious gastrointestinal condition
- • Neurologic or cognitive impairment that prevents safe swallowing
- • Recent history (\<1 year) of cancer that still requires ongoing treatment
- • Recent use of antibiotics 1 month prior to participation in the trial
- • History of cardiac disease
- • History of active renal dysfunction
- • Presence of any absolute contraindication to PEG bowel preparation according to manufacturer labeling
About Centre Hospitalier De L'université De Montréal (Chum)
The Centre Hospitalier de l'Université de Montréal (CHUM) is a leading academic health institution in Canada, dedicated to advancing patient care through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUM is committed to leveraging its multidisciplinary expertise and state-of-the-art facilities to facilitate groundbreaking studies that enhance medical knowledge and improve health outcomes. Collaborating with a network of healthcare professionals and researchers, CHUM fosters a rigorous research environment that prioritizes patient safety, ethical standards, and scientific integrity, positioning itself at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Arielle Elkrief, MD
Principal Investigator
Centre hospitalier de l'Université de Montréal (CHUM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported